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malignancy is less well defined than for the myeloid counterparts. 
Between Jan 83 and Sept 02, 86 such patients (pts) proceeded to 
allogeneic HSCT at the Leukemia/BMT Program of BC. Diag- 
noses (dx) included ALL in 37 (12 Ph+), NHL  in 27 (2 special- 
Burkitt's or lymphoblastic lymphoma; 14 aggressive or trans- 
formed; 11 indolent), CLL in 3, PLL in 1, and myeloma in 18 pts. 
Median (reed) age was 36 (range 12-53) yrs; 52 (60%) were male. 
Med interval dx to HSCT was 9.7 mos (range 1.6 mos to 14.7 yrs). 
Disease status was intermediate or advanced in the majority (7I 
pts, 83%). Donors were mmrd in 14 cases (1 Ag mm in 13, 2 Ag 
mm in 1 pt), and UD in 72 pts (1 Ag mm in 14 pts, 2 Ag mm in 1, 
the remainder HLA matched). Stem cell source was marrow in the 
majority (n=82, 95%); peripheral blood (pb) alone in 2 cases and 
pb + marrow in 2. Conditioning included TBI for most (79pts, 
92%). GVHD prophylaxis was CSP + MTX +/- other for 71 
(82%); T-cell depletion was employed in I2 cases (14%). Engraft- 
ment  (range) of ANC > 0.Sx109/L; WBC > I.OxlOp/L and 
platelets > 20xlO9/L; occurred a reed of 19 (9-33); 20 (9-32); and 
27 (6-124) days respectively. Graft failure occurred in 4 pts. Inci- 
dence of acute GVHD grades II-W; III-1V and chronic GVHD 
was 74%; 46%; and 76%. Thirty-three pts (38%) survive a reed of 
3.6 yrs (range 1 mo - 12 yrs) post HSCT. Fifty three pts (62%) 
are deceased, 19 with relapse (REL) a reed of 353 days and 34 
with non-relapse mortality (NRM) a med of 66 days post HSCT. 
For NRM deaths, GVHD contributed in 21 pts, infection in 7 
including 3 cases of EBV assoc LPD, and RRT in 6 (5 puhn, 1 
VOD) to the cause of death. Four patients have sustained avascu- 
lar necrosis of large joints. Cumulative incidence estimates of 
NRM; REL; EFS and OS are 42%; 31%; 28% and 31%. In con- 
clusion: 1. About 1/3 of pts with lymphoid malignancies receiving 
HSCT from alternative donors achieved long-term survival, with 
the lead pts out more than 10 years. 2. The incidence of relapse is 
reasonable but still significant in this cohort where 'graft vs malig- 
nancy' would be expected to be strongly operative. 3. GVHD and 
infection remain challenging problems in this setting. 
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Between 4/2001 and 8/2002 16 patients 44-72 years old (median 
63) received non-ablative stem cell transplantation with Sirolimus 
(Siro) + Tacrolimus (Tacro) immunoprophy]axis. Diagnoses were: 
AML - 8, NHL  - ~, ALL - 1, CML/Philadelphia negative - 1, and 
CLL-1. Patients had failed 1-5 chemotherapy regimens. All 
received Fludarabine 25rag/m2 d-7 to -3 and Cyclophosphamide 
1 gin/m2 d-7 and -6. Siro began d-7 and Tacro d-3. Both were 
targeted to 5-10ng/lnl. SCT was dO and MTX 5rag/m2 dl, 3 and 
6. Patients with 3/6 or 4/6 matched donors received ATG d-l, 1, 
3, and 5. Patient-donor matches were: 6 -5/6 HLA matched, 3 - 
4/6 matched, 2 3/6 matched, 4 matched unrelated donors - all 
peripheral SCT. One received 4/6 matched cord blood cells. Sur- 
vival at 100-days was 86.66% (i3/I5). Overall survival was 62.5% 
(10/16 Pts, median follow-up d184). The cord blood recipient 
died d26 without stable engraftment. 4 of 5 patients with 3/6 or 
4/6 matched onors died, d37 (cerebrovascular ccident), d32 and 
d158 (coinplications of GVHD). Two died of leukemia d170 and 
d119. All others remain alive including one with a 4/6-matched 
donor -d315. 11/12 (91.6%) alive at day 100 had >95% donor 
engrafunent. One 5/6 matched recipient had only transient donor 
chimerism but recovered with autologous cells. 15/16 patients 
achieved ANC >500/ul (d5-19, median dl0.) 14/16 patients 
achieved platelets >50, 000/ul (d10-60, median dis  - in 2 platelets 
were never <50, 000/uh) Most patients developed elevated creati- 
nine - Max 0.7 to 6.Smg/dl (median 2.95mg/dl). No dialysis was 
required, but creatinine >2.Smg/dl d40-150 prompted withdrawal 
of Tacro in 5 patients. Three had Tacro withdrawn per protocol 
because of risk of relapse. In only one has Tacro tapering clearly 
resulted in GVHD (grade 2, skin). Max cholesterol was 122-527 
mg/dl (median 295.5 mg/dI) and triglyccrides 123-1366mg/dl 
(median 427mg/dl). Drug levels had no correlation with renal or 
lipid toxicities or engraftment. GVHD was: none -4 pts, grade 2 
in 11, grade 3 in I by day 100. Tacro l imus and Sirol imus 
immunoprophylaxis yields relatively effective engraftment in eld- 
erly and poor prognosis patients receiving alternative and hap- 
loidentical donor stem cell transplautation. 
IMMUNE RECONSTITUTION 
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RECONSTITUTION OF NR CELL RECEPTOR REPERTOIRE FOLLOWING 
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The interactions between killer immunoglobulin-like r ceptors 
(KIR) and their human leukocyte antigen (HLA) class I ligands 
are important for NK cell functions and evelopment of NK cell 
receptor repertoires. The fact that both KIR and HLA class I, 
encoded on separate chromosomes, are highly polymorphic pre- 
dicts that the majority of hematopoietic cell transplantations will 
be KIR-mismatched. Consequently, we have used allogeneic 
transplantation as a tool to examine development of NK cell 
receptor epertoires under conditions of KIR and/or I ILA differ- 
ence. Eighteen leukemia patients receiving transplants and their 
donors were analyzed for KIR genotype. Ten  of 13 HLA- 
matched sibling transplants were K/R mismatched while three 
were matched. All unrelated transplants were K/R-mismatched. 
Reconstitution of NK receptor epertoire was examined follow- 
ing t ransplantat ion by flow cytometry using KIR and 
CD94:NKG2A-speeif ic monoclonal antibodies. Three distinct 
patterns of reconstitution were observed. Eight patients reconsti- 
tuted NK cell repertoires like that of the donor and distinct from 
the recipient within the first year post-transplantation. I  con- 
trast, five patients exhibited a generally depressed frequency of 
KIR-expressing NK cells, while CD94:NKG2A expression 
remained high during the first year post transplantation. In three 
of these patients analyzed three years post-transplant, the fre- 
quency of KiR-expressing NK cells had increased to donor lev- 
els. The remaining five patients experienced severe clinical com- 
pl ications fol lowing transplantat ion and displayed unique 
patterns of reconstitution. These results demonstrate that KIR- 
mismatch occurs in the majority of H/~/-matched hematopoietic 
cell transplants and that most patients reconsitute donor-type 
KIR phenotypes. Prelimina W results fi'om a larger study to exam- 
ine the impact of K/R-mismatch on transplant outcome will be 
presented. 
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ENHANCED T-CELL NEOGENESIS FOLLOWING NON-MYELOABLATIVE 
ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA- 
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Measurements of T ceil reconstitution after adult allogencic 
hematopoietic stem cell transplant provide early biologic corre- 
lates for the clinical endpoints of fimctional inmmnity and disease 
free smwivah Quantitative PCR for T cell receptor excision circles 
(TREC) is an accurate measurement of the generation of new T 
cells from undifferentiated hematopoietic stem cells and thus pro- 
vides an assessment of thymic function in vivo. Previous studies 
have shown that myeloablative regimens markedly reduce thymic 
output of new T cells for 6-9 months following allogeneic trans- 
plant. Moreover, reduced levels of TREC correlate with decreased 
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